[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol, 2014, 14(10): 667-685.
[3] Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature, 2014, 513(7516): 59-64.
[4] Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut, 2019, 68(6): 1014-1023.
[5] Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology, 2019, 69(1): 107-120.
[6] Mu Q, Kirby J, Reilly CM, et al. Leaky gut as a danger signal for autoimmune diseases. Front Immunol, 2017, 8: 598.
[7] de Kort S, Keszthelyi D, Masclee AA. Leaky gut and diabetes mellitus: what is the link? Obes Rev, 2011, 12(6): 449-458.
[8] Stevenson BR, Siliciano JD, Mooseker MS, et al. Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J Cell Biol, 1986, 103(3): 755-766.
[9] Furuse M, Fujita K, Hiiragi T, et al. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol, 1998, 141(7): 1539-1550.
[10] Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut, 2019, 68(8): 1516-1526.
[11] Higashi Y, Suzuki S, Sakaguchi T, et al. Loss of claudin-1 expression correlates with malignancy of hepatocellular carcinoma. J Surg Res, 2007, 139(1): 68-76.
[12] Fedirko V, Tran HQ, Gewirtz AT, et al. Exposure to bacterial products lipopolysaccharide and flagellin and hepatocellular carcinoma: a nested case-control study. BMC Med, 2017, 15(1): 72.
[13] Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell, 2012, 21(4): 504-516.
[14] Ma C, Han M, Heinrich B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science, 2018, 360(6391).
[15] Yu LX, Yan HX, Liu Q, et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology, 2010, 52(4): 1322-1333.
[16] Loo TM, Kamachi F, Watanabe Y, et al. Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity. Cancer Discov, 2017, 7(5): 522-538.
[17] Sanchez B. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis: a role for bifidobacteria and lactobacilli? Nat Rev Gastroenterol Hepatol, 2018, 15(4): 205.
[18] Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol, 2018, 15(2): 111-128.
[19] Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature, 2013, 499(7456): 97-101.
[20] Singh V, Yeoh BS, Chassaing B, et al. Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer. Cell, 2018, 175(3): 679-694 e622.
[21] Zhang X, Coker OO, Chu SH et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut, 2020[ahead of print] .
[22] Cho EJ, Leem S, Kim SA, et al. Circulating microbiota-based metagenomic signature for detection of hepatocellular carcinoma. Sci Rep, 2019, 9(1): 7536.
[23] Li J, Sung CY, Lee N, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci U S A, 2016, 113(9): E1306-1315. |
